About Jounce Therapeutics
Jounce Therapeutics is a company based in Cambridge (United States) founded in 2013 was acquired by Concentra Biosciences in March 2023.. Jounce Therapeutics has raised $139 million across 4 funding rounds from investors including Celgene, Casdin Capital and Nextech Invest. The company has 137 employees as of December 31, 2021. Jounce Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
- Headquarter Cambridge, United States
- Employees 137 as on 31 Dec, 2021
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Jounce Therapeutics, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$139 M (USD)
in 4 rounds
-
Latest Funding Round
$35 M (USD), Post-IPO
Oct 29, 2020
-
Investors
Celgene
& 9 more
-
Employee Count
137
as on Dec 31, 2021
-
Acquired by
Concentra Biosciences
(Mar 27, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Funding Insights of Jounce Therapeutics
Jounce Therapeutics has successfully raised a total of $139M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $35 million completed in October 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Post-IPO — $35.0M
-
First Round
First Round
(14 Feb 2013)
- Investors Count 9
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2020 | Amount | Post-IPO - Jounce Therapeutics | Valuation |
investors |
|
| Jul, 2016 | Amount | Series C - Jounce Therapeutics | Valuation | Celgene |
|
| Apr, 2015 | Amount | Series B - Jounce Therapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Jounce Therapeutics
Jounce Therapeutics has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include Celgene, Casdin Capital and Nextech Invest. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investing in Life Sciences sectors like Healthcare and Biotechnology.
|
Founded Year | Domain | Location | |
|
PE firm investing in the US
|
Founded Year | Domain | Location | |
|
Multi-stage investment firm invests in healthcare and life sciences companies
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Jounce Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Jounce Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Jounce Therapeutics Comparisons
Competitors of Jounce Therapeutics
Jounce Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| domain | founded_year | HQ Location |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cancer and rare diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Jounce Therapeutics
Frequently Asked Questions about Jounce Therapeutics
When was Jounce Therapeutics founded?
Jounce Therapeutics was founded in 2013.
Where is Jounce Therapeutics located?
Jounce Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Is Jounce Therapeutics a funded company?
Jounce Therapeutics is a funded company, having raised a total of $139M across 4 funding rounds to date. The company's 1st funding round was a Series B of $56M, raised on Feb 14, 2013.
How many employees does Jounce Therapeutics have?
As of Dec 31, 2021, the latest employee count at Jounce Therapeutics is 137.
What does Jounce Therapeutics do?
Jounce Therapeutics was founded in 2013 in Cambridge, United States, as a clinical-stage immunotherapy company. Discovery and development of cancer treatments are focused on, with a pipeline emphasizing monoclonal antibodies. The lead candidate, JTX-2011, binds to Inducible T cell Co-Stimulator to activate immune responses against tumors. Studies on the tumor microenvironment, particularly tumor-associated macrophages, are conducted to advance potential immunotherapies across various cancers.
Who are the top competitors of Jounce Therapeutics?
Jounce Therapeutics's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Who are Jounce Therapeutics's investors?
Jounce Therapeutics has 10 investors. Key investors include Celgene, Casdin Capital, Nextech Invest, Wellington, and Foresite Capital.